Tetrabenazine

Nature Reviews Drug Discovery

Volumn 8, Issue 1, 2009, Pages 17-18

  Hayden, Michael R ^a   Leavitt, Blair R ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CREATINE; HALOPERIDOL; MINOCYCLINE; NEUROLEPTIC AGENT; PLACEBO; TETRABENAZINE; UBIDECARENONE;

AKATHISIA; ARTICLE; BRADYKINESIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DYSPHAGIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUNTINGTON CHOREA; INSOMNIA; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUICIDE; WEIGHT GAIN;

ADRENERGIC UPTAKE INHIBITORS; CHOREA; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; HUNTINGTON DISEASE; TETRABENAZINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 58149189835     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2784     Document Type: Article

References (15)

1. Leavitt, & B. R. & Hayden, M. R. in Kelley's Textbook of Internal Medicine. 4th ed. (Lippincott, Williams and Wilkins, Philadelphia, 2000).
2. Landles, C. & Bates, G. P. Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO Rep. 5, 958-963 (2004).
3. Graham, R. K. et al. Cleavage at the caspase 6 site in huntingtin is required for motor dysfunction, neurodegeneration and excitotoxicity in Huntington Disease. Cell 125, 1179-1191 (2006).
4. Grimbergen, Y. A & Roos, R. A. Therapeutic options for Huntington's disease. Curr. Opin. Invest. Drugs 4, 51-54 (2003).
5. Quinn, G. P., Shore, P. A. & Brodie, B. B. Biochemical and pharmacological studies of RO1-9569 (tetrabenazine), a non-indole tranquilizing agent with reserpine-like effects. J. Pharmacol. Exp. Ther. 127, 103-109 (1959).
6. Dalby, M. A. Effect of tetrabenazine on extrapyramidal movement disorders. BMJ 2, 422-423 (1969).
7. Jankovic, J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv. Neurol. 37, 227-289 (1983).
8. Ondo, W. G. et al. Tetrabenazine treatment for Huntington's disease associated chorea. Clin. Neuropharmacol. 25, 300-302 (2002).
9. Zheng, G., Dwoskin, L. P. & Crooks, P. A. Vesicular monoamine transporter 2: Role as a novel target for drug development. AAPS J. 8, E682-E692 (2006).
10. Food and Drug Administration. FDA labelling information. FDA web site [online], (2008).
11. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 66 366-372 (2006).
12. Frank, S. et al. Functional decline due to chorea in Huntington's disease. Neurology 62, A204 (2004).
13. National Institute of Neurological Disorders and Stroke (NINDS). Huntington's disease: Hope through research. NINDS web site [online], (2008).
14. IMS MIDAS (2007).
15. Gibbs, L. NewCrest Biovail Research Report (New Crest, 8 Oct 2008).